Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 417 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FDG-PET scanning Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Observational

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

NCT02608619
View directory record Official record
Conditions
Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
Interventions
F-choline PET Scan, FDG-PET, biopsy
Radiation · Device · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

NCT05564403
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Observational

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

NCT01664936
View directory record Official record
Conditions
Head and Neck Cancers
Interventions
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated No phase listed Observational

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

NCT06566209
View directory record Official record
Conditions
Subclinical Immune Checkpoint Inhibitor-Induced Myocarditis, Myocarditis, ICI-Myocarditis, Solid Malignant Tumor, Hematologic Malignancy, Subclinical Myocarditis, Subclinical ICI-myocarditis
Interventions
Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

NCT03549598
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Not applicable Interventional Results available

Infiltration Effect on SUV

NCT03320564
View directory record Official record
Conditions
Dose Response Relationship, Drug
Interventions
F-18 FDG PET
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Phase 1 Interventional

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

NCT02379377
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma, Benign Liver Tumor, Metastases to Liver
Interventions
Fluorine F 18 L-glutamate Derivative 18F-FSPG, Carbon C 11 Acetate, Positron Emission Tomography, Laboratory Biomarker Analysis, Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Biological · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

NCT07859800
View directory record Official record
Conditions
Healthy Volunteer, Malaria
Interventions
18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
View directory record Official record
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Not applicable Interventional

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

NCT02042053
View directory record Official record
Conditions
Prostate Cancer
Interventions
PET/CT, PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional

Brain Inflammation and Function in Alcoholism

NCT02233868
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
connectivity, neuroinflammation, neurofunction
Other · Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
30 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional Results available

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT02226276
View directory record Official record
Conditions
Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, trastuzumab, copper Cu 64-DOTA-trastuzumab, ado-trastuzumab emtansine, laboratory biomarker analysis
Radiation · Procedure · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

NCT02448225
View directory record Official record
Conditions
Lung Carcinoma, Solitary Pulmonary Nodule, Cigarette Smoking Behavior
Interventions
Computed Tomography, fluorodeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Laboratory Biomarker Analysis, Positron Emission Tomography, Positron Emission Tomography (PET)
Procedure · Radiation · Drug + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

NCT03318497
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

[18F]FES PET/.CT in Uterine Cancer

NCT05916196
View directory record Official record
Conditions
Uterine Cancer
Interventions
18F-Fluoroestradiol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Phase 1 Interventional

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02390635
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions
Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI
Procedure · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

NCT01543659
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr-DFO-huJ591
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

NCT06984861
View directory record Official record
Conditions
Oropharyngeal Carcinoma
Interventions
18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
View directory record Official record
Conditions
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
180 Days to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
107
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 84 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly

NCT00811122
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PIB PET Scan, FDG-PET Scan
Radiation
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 20, 2026, 5:39 PM EDT